Accessibility Menu
Hikma Pharmaceuticals Plc logo

Hikma Pharmaceuticals Plc(OTC) HKMPY

Current Price$41.27
Market Cap$4.32BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+126%
5 Year-36%
1 Year-22%
1 Month+4%
Hikma Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 41.272026-07-23
Hikma Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.73%USD 42.002026-07-16
1 month+3.62%USD 39.832026-06-23
3 month+10.91%USD 37.212026-04-24
Year to date+1.28%USD 40.752025-12-31
1 year-21.63%USD 52.662025-07-23
3 year-15.02%USD 48.572023-07-24
5 year-35.89%USD 64.372021-07-23
Since inception+126%USD 18.262011-03-28

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

$4.32BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.47B

Net Income (TTM)

$759.05M

EPS (TTM)

$3.64

P/E Ratio

11.30

Dividend

$1.68

Beta (Volatility)

0.36 (Low)

Price

$41.27

Volume

399

Open

$41.41

Previous Close

$41.27

Daily Range

$41.27 - $41.41

52-Week Range

$31.80 - $54.40

Estimated Earnings Date

Feb 24, 2026

HKMPY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC is a global pharmaceutical company specializing in the development, production, and distribution of a diverse range of generic, branded, and in-licensed medicines. The company operates through three main divisions: Injectables, Generics, and Branded products, serving various therapeutic areas across multiple international markets.

Products and Services
  • Injectables division focuses on generic injectable medications for hospitals
  • Generics segment offers oral and non-injectable formulations for retail
  • Branded products include licensed drugs for retail and hospital use
Growth Outlook
  • Revenue increased to $1.68 billion in Q4 2025, reflecting strong demand
  • Net income rose to $163 million in Q4 2025, showcasing profitability
  • Operating income margin improved to 18% in Q4 2025, indicating operational efficiency
Financial Highlights
  • Trailing twelve months (TTM) revenue of $6.5 billion, demonstrating consistent growth
  • Dividend yield of 4.13%, providing attractive returns to shareholders
  • Net profit margin of 12% TTM, reflecting effective cost management
Hikma Pharmaceuticals PLC has established a robust presence in the pharmaceutical industry, with a focus on delivering high-quality medications across various therapeutic areas. The company's strategic divisions allow it to cater to both hospital and retail markets, enhancing its competitive edge. Recent financial performance indicates a positive trajectory, with significant revenue growth and improved profitability metrics. The company's commitment to innovation and operational efficiency positions it well for future expansion in the global pharmaceutical landscape.
AI Generated • Jul 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,400

CEO

Riad Mishlawi

Website

www.hikma.com

Headquarters

London, GL W1S 2HR, GB

HKMPY Financials

Key Financial Metrics (TTM)

Gross Margin

41.35%

Operating Margin

16.81%

Net Income Margin

12.00%

Return on Equity

15.83%

Return on Capital

13.57%

Return on Assets

7.10%

Earnings Yield

8.85%

Dividend Yield

4.07%

Payout Ratio

45.16%

Stock Overview

Market Cap

$4.32BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

104.71M

Volume

399

Avg. Volume

279.871

Financials (TTM)

Gross Profit

$2.76B

Operating Income

$1.15B

EBITDA

$1.62B

Operating Cash Flow

$907.65M

Capital Expenditure

-$359.02M

Free Cash Flow

$548.63M

Cash & ST Invst.

$354.00M

Total Debt

$1.60B

Hikma Pharmaceuticals Plc Performance Analysis

Hikma Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,515,446,660-1.5%
20232023-12-31USD 2,886,143,70614.7%
20242024-12-31USD 3,128,315,8068.4%
20252025-12-31USD 3,356,826,1807.3%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-309.2%
Q42024-12-31-0.7%
Q22025-06-306.4%
Q42025-12-311.6%
Hikma Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.67-53.8%
20232023-12-31USD 1.722.7%
20242024-12-31USD 3.2187.4%
20252025-12-31USD 3.6212.6%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30288.5%
Q42024-12-31-41.6%
Q22025-06-3081.4%
Q42025-12-31-30.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.68B

+17.3%

Gross Profit

$667.49M

+7.1%

Gross Margin

39.62%

N/A

Market Cap

$4.32BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$459.73K

N/A

Employees

9,400

N/A

Net Income

$163.39M

+179.1%

EBITDA

$407.47M

+90.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$354.00M

+54.6%

Total Debt

$1.60B

+34.7%

Accounts Receivable

$1.08B

+36.8%

Inventory

$1.11B

+24.1%

Long Term Debt

$1.49B

+44.7%

Short Term Debt

$114.00M

-29.2%

Return on Assets

7.10%

N/A

Return on Invested Capital

13.38%

N/A

Free Cash Flow

$101.89M

-58.8%

Operating Cash Flow

$229.56M

-33.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNPUFSumitomo Pharma Co., Ltd.
$8.41+0.00%
ZLDPFZealand Pharma A/S
$45.02+0.01%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
OPHLFOno Pharmaceutical Co., Ltd.
$14.61+9.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.00-0.03%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$31.27-0.14%

Questions About HKMPY

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at $41.27 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between $31.80 and $54.40.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of $1.60B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported $328.00M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 4.07%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services